Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
54 hedge funds and large institutions have $77.2M invested in Kezar Life Sciences in 2019 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 10 reducing their positions, and 7 closing their positions.
140% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 10
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
8% more funds holding
Funds holding: 50 → 54 (+4)
0.05% more ownership
Funds ownership: 5.19% → 5.24% (+0.05%)
56% less capital invested
Capital invested by funds: $176M → $77.2M (-$98.7M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$19.1M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$3.69M |
| 3 |
BlackRock
New York
|
+$3.25M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.74M |
| 5 |
FM
Frazier Management
Seattle,
Washington
|
+$1.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.16M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$4.25M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.65M |
| 4 |
SC
Slow Capital
Greenbrae,
California
|
-$3.65M |
| 5 |
CI
Cowen Inc
New York
|
-$2.32M |
KZR Hedge Fund Activity: Q2 2019 in Review
54 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q2 2019, worth a combined $77.2M — down 56% from $176M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new KZR positions and 7 closed out — a net gain of 7 holders — while 24 added to existing stakes and 10 trimmed.
The largest buyer was Bellevue Group, opening a new position worth an estimated $19.1M. The largest seller was Cormorant Asset Management, cutting an estimated $5.16M.
- 54 institutional investors held Kezar Life Sciences (KZR) as of Q2 2019, up from 50 in Q1 2019.
- Funds reported $77.2M of Kezar Life Sciences stock for Q2 2019, down 56% quarter-over-quarter.
- 14 funds opened new Kezar Life Sciences positions in Q2 2019 and 7 closed out, a net change of +7 holders.
- The largest Kezar Life Sciences buyer in Q2 2019 was Bellevue Group, an estimated $19.1M added.
- The largest Kezar Life Sciences seller in Q2 2019 was Cormorant Asset Management, an estimated $5.16M sold.
Based on aggregated 13F filings for Q2 2019.